Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling [0.03%]
评估生物疗法治疗阵发性睡眠性血红蛋白尿症的进展：重点关注患者分层和预后标志物
Francesco Versino,Bruno Fattizzo
Francesco Versino
Introduction: Complement inhibition has revolutionized paroxysmal nocturnal hemoglobinuria (PNH) treatment. While eculizumab, the first anti-C5 antibody, reduced intravascular hemolysis (IVH) and thrombotic risk, it requi...
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety and immunogenicity of BAT1806 SC with Tocilizumab in healthy Chinese male subjects [0.03%]
托珠单抗BAT1806与雅美罗在健康受试者中的随机、双盲、单次给药、平行对照的生物等效性及免疫原性Ⅰ期临床试验
Qin Yang,Yan Jiang,Zhijie Liu et al.
Qin Yang et al.
Background: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with Tocilizumab (RoActemra®) in healthy C...
Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis [0.03%]
风湿性关节炎患者换用生物仿制药adalimumab-atto后的临床和自付费用结果
Antony T-H Lin,Fang Niu,Rita L Hui et al.
Antony T-H Lin et al.
Background: Limited real-world studies have evaluated outcomes after switching treatment from a reference product (RP) to a biosimilar product. The objective of this real-world study was to assess the outcomes of switchin...
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis [0.03%]
尼波卡利姆治疗全身性重症肌无力的评估研究
Carlo Antozzi,Marie Fitzgibbon
Carlo Antozzi
Introduction: Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies targeting the neuromuscular junction. MG, characterized clinically by fluctuating muscle weakness and fatigability, is traditionally t...
Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis [0.03%]
利妥昔单抗治疗类风湿关节炎相关间质性肺病的疗效和安全性：系统评价和 Meta分析
Mahmoud Ines,Zarrouk Zeineb,Bouden Selma et al.
Mahmoud Ines et al.
Objectives: To assess the effectiveness and safety of Rituximab (RTX) treatment among patients diagnosed with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). ...
Correction [0.03%]
改正措施
Published Erratum
Expert opinion on biological therapy. 2025 Sep 10:1. DOI:10.1080/14712598.2025.2559467 2025
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies [0.03%]
非小细胞肺癌术前治疗的单克隆抗体使用及影响分析
Danilo Rocco,Luigi Della Gravara,Cristina Boccia et al.
Danilo Rocco et al.
Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunot...
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions [0.03%]
联合应用VEGF和PD-1/PD-L1抑制剂治疗晚期肝细胞癌：临床试验、真实世界证据及未来方向
Rita Balsano,Martina Pino,Elisa Bocchero et al.
Rita Balsano et al.
Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with most of patients diagnosed at advanced stage. Thus, systemic therapy remains a cornerstone of treatment. In ...
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management [0.03%]
胃肠病学中的生物类似药的有效性和安全性：关注炎症性肠病的管理
Fruzsina Balogh,Dorottya Angyal,Adam Varga et al.
Fruzsina Balogh et al.
Introduction: The introduction of biosimilars changed the management of biologicals in inflammatory bowel disease (IBD) since the approval of CT-P13, the first biosimilar to infliximab, by the European Medicines Agency (E...
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics [0.03%]
转移性结直肠癌的个体化治疗：生物标志物指导下的生物制剂使用
Francesco Sullo,Chiara Gallio,Laura Matteucci et al.
Francesco Sullo et al.
Introduction: Metastatic colorectal cancer (mCRC) remains a leading cause of cancer mortality worldwide, with limited long-term survival despite therapeutic advances. The increasing understanding of its molecular heteroge...